Monoctanoin
Moctanin (monoctanoin) is a small molecule pharmaceutical. Monoctanoin was first approved as Moctanin on 1985-10-29.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Monoctanoin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MOCTANIN | Ethitek Pharmaceuticals | N-019368 DISCN | 1985-10-29 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
142 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | D005221 | HP_0012378 | R53.83 | 2 | 4 | 4 | 3 | 2 | 15 |
| Healthy volunteers/patients | — | 8 | — | — | 1 | 4 | 13 | ||
| Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | 2 | — | 4 | 1 | 9 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | 2 | 2 | 1 | 6 |
| Psychotic disorders | D011618 | F20.81 | 1 | — | — | 2 | — | 3 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 1 | 1 | 1 | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 1 | 1 | — | 2 |
| Sleep initiation and maintenance disorders | D007319 | F51.01 | — | — | — | 2 | — | 2 | |
| Delayed emergence from anesthesia | D055191 | — | — | — | 1 | — | 1 | ||
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 1 | — | 1 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | F14 | 4 | 15 | 1 | — | 3 | 22 | |
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | 3 | 6 | — | 3 | 12 |
| Neoplasms | D009369 | C80 | 1 | 2 | 3 | — | 1 | 7 | |
| Disorders of excessive somnolence | D006970 | G47.1 | — | 1 | 2 | — | 2 | 5 | |
| Cataplexy | D002385 | — | — | 2 | — | 1 | 3 | ||
| Sleep wake disorders | D012893 | G47 | — | 1 | 1 | — | 1 | 3 | |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | 2 | — | — | 3 |
| Cognitive dysfunction | D060825 | G31.84 | 1 | — | 1 | — | 1 | 3 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 2 | — | — | 3 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 2 | — | — | 2 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | 1 | — | — | 1 | 4 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | 3 | — | — | — | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | — | — | 1 | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 2 | — | — | 1 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | 2 | 3 |
| Depression | D003863 | F33.9 | — | 1 | — | — | 1 | 2 | |
| Central nervous system neoplasms | D016543 | — | 1 | — | — | 1 | 2 | ||
| Tachycardia | D013610 | HP_0001649 | R00.0 | 1 | 1 | — | — | — | 1 |
| Orthostatic intolerance | D054971 | 1 | 1 | — | — | — | 1 | ||
| Postoperative cognitive complications | D000079690 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 1 | — | — | — | — | 1 | ||
| Pure autonomic failure | D054970 | 1 | — | — | — | — | 1 | ||
| Orthostatic hypotension | D007024 | I95.1 | 1 | — | — | — | — | 1 | |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | 1 | — | — | — | — | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | 1 | — | — | — | — | 1 | |
| Sleep deprivation | D012892 | F51.12 | 1 | — | — | — | — | 1 | |
| Postural orthostatic tachycardia syndrome | D054972 | G90.A | 1 | — | — | — | — | 1 | |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | — | — | — | 1 |
| Biliary liver cirrhosis | D008105 | K74.3 | 1 | — | — | — | — | 1 | |
| Tinnitus | D014012 | HP_0000360 | H93.1 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | 1 | 1 | |
| Glucose metabolism disorders | D044882 | — | — | — | — | 1 | 1 | ||
| Circadian rhythm sleep disorders | D020178 | G47.2 | — | — | — | — | 1 | 1 | |
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Critical illness | D016638 | — | — | — | — | 1 | 1 | ||
| Creativity | D003405 | — | — | — | — | 1 | 1 | ||
| Motivation | D009042 | — | — | — | — | 1 | 1 | ||
| Reward | D012201 | — | — | — | — | 1 | 1 | ||
| Weight gain | D015430 | HP_0004324 | — | — | — | — | 1 | 1 | |
| Traumatic brain injuries | D000070642 | S06 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MONOCTANOIN |
| INN | — |
| Description | 1-monooctanoylglycerol is a 1-monoglyceride that has octanoyl as the acyl group. It is a 1-monoglyceride and an octanoate ester. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC.CCCCCCCC(=O)OCC(O)CO.CCCCCCCCCC(=O)OCC(O)CO.OCC(O)CO |
Identifiers
| PDB | — |
| CAS-ID | 502-54-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301678 |
| ChEBI ID | — |
| PubChem CID | 3033877 |
| DrugBank | DB06801 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,029 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more